J&J Covid-19 Vaccine Was 66 Percent Effective in Late-Stage Study

Johnson & Johnson has announced that its experimental COVID-19 vaccine was 66 percent effective at protecting people from moderate to severe disease in a large clinical trial, reports the Wall Street Journal . The positive results could pave the way for its deployment throughout the United States within weeks. The J&J vaccine appeared to be generally safe and well tolerated among the more than 44,300 adults aged 18 and older in the late-stage trial, though some of the volunteers reported temporary side effects like fever. The company is expected to ask American regulators as soon as next week to authorize use. The FDA could take action by the end of February. If the shot is approved, federal officials say J&J will be able to quickly ship millions of doses.